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a b s t r a c t
Serotonergic mechanisms play a central role in migraine pathology. However, the region-speciﬁc effects
of serotonin (5-HT) mediated via multiple types of receptors in the nociceptive system are poorly un-
derstood. Using extracellular and patch-clamp recordings, we studied the action of 5-HT on the excit-
ability of peripheral and central terminals of trigeminal afferents. 5-HT evoked long-lasting TTX-sensitive
ﬁring in the peripheral terminals of meningeal afferents, the origin site of migraine pain. Cluster analysis
revealed that in majority of nociceptive ﬁbers 5-HT induced either transient or persistent spiking activity
with prevailing delta and theta rhythms. The 5-HT3-receptor antagonist MDL-72222 or 5-HT1B/D-re-
ceptor antagonist GR127935 largely reduced, but their combination completely prevented the excitatory
pro-nociceptive action of 5-HT. The 5-HT3 agonist mCPBG activated spikes in MDL-72222-dependent
manner but the 5HT-1 receptor agonist sumatriptan did not affect the nociceptive ﬁring. 5-HT also
triggered peripheral CGRP release in meninges, which was blocked by MDL-72222.5-HT evoked fast
membrane currents and Ca2þ transients in a fraction of trigeminal neurons. Immunohistochemistry
showed expression of 5-HT3A receptors in ﬁbers innervating meninges. Endogenous release of 5-HT
from degranulated mast cells increased nociceptive ﬁring. Low pH but not histamine strongly acti-
vated ﬁring. 5-HT reduced monosynaptic inputs from trigeminal Ad- and C-afferents to the upper cervical
lamina I neurons and this effect was blocked by MDL-72222. Consistent with central inhibitory effect, 5-
HT reduced CGRP release in the brainstem slices. In conclusion, 5-HT evokes powerful pro-nociceptive
peripheral and anti-nociceptive central effects in trigeminal system transmitting migraine pain.
© 2016 Elsevier Ltd. All rights reserved.
1. Introduction
Migraine is a common neurological disorder which patho-
physiology is still poorly understood. For decades, serotonergic
mechanisms were supposed to play a key role in migraine pa-
thology (Lance et al., 1967; Dussor, 2014; Hamel, 2007). During
migraine attacks, the plasma level of serotonin (5-HT) raises
dramatically, whereas between attacks it goes down (Ferrari et al.,
1989). Early studies reported the ability of 5-HT to inhibit migraine
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